Showing results (271-280 of 335) with videos related to

Sort By:
Pageof 34
British Journal of Cancer|January 24, 2018
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 21, 2015
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancerGina Song, Teresa K Tarrant, Taylor F White, et al.
British Journal of Cancer|March 13, 2018
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumoursJordan Berlin, Ramesh K Ramanathan, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Annals of Surgical Oncology|August 2, 2013
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinomaGeorge Van Buren, Ramesh K Ramanathan, Alyssa M Krasinskas, et al.
Archives of Internal Medicine|March 21, 1998
The relationship between cardiothoracic ratio and left ventricular ejection fraction in congestive heart failure. Digitalis Investigation GroupE F Philbin, R Garg, K Danisa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid TumorsAmita Patnaik, Glen J Weiss, John E Leonard, et al.
Investigational New Drugs|December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignanciesGlen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741Howard L McLeod, Daniel J Sargent, Sharon Marsh, et al.
Pageof 34